全文获取类型
收费全文 | 36599篇 |
免费 | 2973篇 |
国内免费 | 676篇 |
专业分类
耳鼻咽喉 | 486篇 |
儿科学 | 436篇 |
妇产科学 | 3833篇 |
基础医学 | 3326篇 |
口腔科学 | 312篇 |
临床医学 | 3460篇 |
内科学 | 3551篇 |
皮肤病学 | 328篇 |
神经病学 | 671篇 |
特种医学 | 1043篇 |
外科学 | 3322篇 |
综合类 | 4146篇 |
一般理论 | 2篇 |
预防医学 | 2715篇 |
眼科学 | 133篇 |
药学 | 2714篇 |
19篇 | |
中国医学 | 765篇 |
肿瘤学 | 8986篇 |
出版年
2024年 | 45篇 |
2023年 | 642篇 |
2022年 | 1336篇 |
2021年 | 1807篇 |
2020年 | 1430篇 |
2019年 | 1880篇 |
2018年 | 1899篇 |
2017年 | 1672篇 |
2016年 | 1358篇 |
2015年 | 1342篇 |
2014年 | 2974篇 |
2013年 | 2621篇 |
2012年 | 2223篇 |
2011年 | 2430篇 |
2010年 | 1691篇 |
2009年 | 1795篇 |
2008年 | 1898篇 |
2007年 | 1632篇 |
2006年 | 1402篇 |
2005年 | 1110篇 |
2004年 | 1005篇 |
2003年 | 777篇 |
2002年 | 524篇 |
2001年 | 561篇 |
2000年 | 488篇 |
1999年 | 428篇 |
1998年 | 336篇 |
1997年 | 312篇 |
1996年 | 272篇 |
1995年 | 260篇 |
1994年 | 243篇 |
1993年 | 172篇 |
1992年 | 136篇 |
1991年 | 97篇 |
1990年 | 94篇 |
1989年 | 105篇 |
1988年 | 83篇 |
1987年 | 77篇 |
1986年 | 51篇 |
1985年 | 131篇 |
1984年 | 152篇 |
1983年 | 117篇 |
1982年 | 150篇 |
1981年 | 107篇 |
1980年 | 89篇 |
1979年 | 83篇 |
1978年 | 52篇 |
1977年 | 31篇 |
1976年 | 38篇 |
1975年 | 29篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
61.
Primary surgical prevention in the form of risk-reducing salpingo-oophorectomy (RRSO) is the most effective option and the gold standard for ovarian cancer (OC) risk-reduction, particularly given the absence of an effective national OC screening programme. However, premenopausal RRSO leads to premature surgical menopause with detrimental long-term health sequelae particularly in women who do not/are unable to take hormone replacement therapy (HRT). HRT uptake in women undergoing pre-menopausal oophorectomy appears low and is dependent on informed counselling, the safety of HRT and efficacy in mitigating the health sequelae of premature menopause. Acceptance of a central role for the fallopian tube in OC etiopathogenesis, coupled with the detrimental consequences of premature menopause, has led to the attractive proposal of early-salpingectomy with delayed oophorectomy as an alternative OC surgical prevention strategy in premenopausal women who have completed childbearing but decline or wish to delay RRSO. The successful implementation of risk reducing surgery for OC prevention depends on the acceptability of surgery to both, recipients (e.g. BRCA1/BRCA2 carriers) and intervention deliverers (healthcare professionals/researchers). Acceptability is also informed by an understanding of health outcomes following risk reducing surgery and the safety of HRT. It is therefore vital to understand the effects of surgery on important health outcomes such as cardiovascular health, neurological function and bone health. We present a comprehensive review of acceptability, the selected health outcomes mentioned above and HRT safety following risk reducing surgery. 相似文献
62.
ObjectiveTo investigate long-term health-related quality of life (HRQoL) changes over time in younger compared to older disease-free breast cancer survivors who participated in a prospective randomized exercise trial.MethodsSurvivors (aged 35–68 years) were randomized to a 12-month exercise trial after adjuvant treatment and followed up for ten years. HRQoL was assessed with the generic 15D instrument during follow-up and the younger (baseline age ≤ 50) and older (age >50) survivors’ HRQoL was compared to that of the age-matched general female population (n = 892). The analysis included 342 survivors.ResultsThe decline of HRQoL compared to the population was steeper and recovery slower in the younger survivors (p for interaction < 0.001). The impairment was also larger among the younger survivors (p = 0.027) whose mean HRQoL deteriorated for three years after treatment and started to slowly improve thereafter but still remained below the population level after ten years (difference −0.017, 95% CI: −0.031 to −0.004). The older survivors’ mean HRQoL gradually approached the population level during the first five years but also remained below it at ten years (difference −0.019, 95% CI: −0.031 to −0.007). The largest differences were on the dimensions of sleeping and sexual activity, on which both age groups remained below the population level throughout the follow-up.ConclusionsHRQoL developed differently in younger and older survivors both regarding the most affected dimensions of HRQoL and the timing of the changes during follow-up. HRQoL of both age groups remained below the population level even ten years after treatment. 相似文献
63.
64.
本文报道了我院收治的卵巢恶性畸胎瘤31例,随访中2例失访,随访率为93.53%。并讨论了卵巢恶性畸瘤的治疗方式为手术加联合化疗,对年轻的I期患者可行患侧单侧附件切除术,术后化疗极为重要。化疗方法采用VAC或PVB方案联合化疗,本文还 影响预后的重要因素为临床分期期和病理学特点. 相似文献
65.
本研究观察国产雌二醇周效贴片(E2贴片)治疗因卵巢功能低落所致的主要临床表现的疗效,结合血FSH、LH、E2测定,阴道脱落细胞成熟指数和部分病例的子宫内膜活检,对E2贴片的疗效进行了综合评价。结果显示,雌二醇周效贴片对卵巢功能低落所致的潮热、出汗、失眠、情绪波动,眩晕和阴道干涩等有显著疗效,且疗效随用药时间的延长而递增,在用药140天时总有效率分别达98.9%,92.0%、91.4%、90.0%和78.0%,对LH、FSH的释放有抑制作用;血清E2水平属轻度升高,但趋于平稳;部分病例子宫内膜组织学检查未见雌激素作用所致的内膜增殖效应。用药期间部分病例出现周期性阴道出血,这对年轻卵巢功能早哀者在生理和心理上均有治疗意义,但对更年期患者会造成不便和不安感。约20%的病例贴片局部有轻微痒感,无其它不良反应。 相似文献
66.
卵巢恶性肿瘤与血小板增多关系分析 总被引:1,自引:0,他引:1
李洁华 《中国现代医药杂志》2005,7(5):48-49
目的探讨卵巢恶性肿瘤伴发血小板增多的临床规律。方法回顾分析98例卵巢恶性肿瘤患者的临床资料,26例合并血小板增多。结果血小板增多占26.5%,其中晚期(Ⅲ+Ⅳ期)占88.46%,晚期患者血小板偏高明显增多,且肿瘤切除后血小板下降。结论卵巢恶性肿瘤伴发血小板增多晚期患者多见,预后差,血小板增多可作为判断卵巢肿瘤恶性程度及术后随访的指标。 相似文献
67.
é. Cavro elodiecavro@hotmail.fr C. Bungener Catherine.Bungener@univ-paris.fr A. Bioy antoine.bioy@bct.aphp.fr 《Revue Francophone de Psycho-Oncologie》2005,4(2):74-79
Résumé: La rémission du cancer peut être l’occasion pour certains patients d’une réelle détresse émotionnelle ainsi que d’une désadaptation psychologique appelées: syndrome de Lazare. Nous émettons trois hypothèses explicatives quant à la survenue de tels troubles. La première confronte l’issue du cancer aux concepts psychanalytiques de dette et de masochisme. La deuxième envisage les symptômes sous l’angle d’une réaction de sevrage. Et la dernière évoque le contrecoup traumatique des traitements.Dossier: «Cliniques du cancer» 相似文献
68.
69.
评估控制性卵巢刺激中预测卵巢反应性的指标 总被引:1,自引:0,他引:1
在辅助生育技术的实施中,控制性卵巢刺激(COS)方案是根据患者情况确定的,在用药剂量和启动时间的掌握上非常重要。由于卵巢本身反应性或基础状态的不同,不同年龄及不同病因的患者有着极大的差异,用量适当可避免因启动剂量过大造成卵巢过度剌激(OHSS),或剂量过少造成低反应,卵泡 相似文献
70.
Riccardo Torta Carlotta Berra Luca Binaschi Roberto Borio 《Supportive care in cancer》2007,15(5):539-546
Introduction Amisulpride is a substituted benzamide that, at low doses, selectively blocks D2 and D3 presynaptic dopamine receptors, enhancing
dopaminergic transmission in frontal cortex and limbic areas. Many clinical studies versus placebo, tricyclic antidepressants
and selective serotonin reuptake inhibitors showed amisulpride antidepressant effect, supporting its safety and rapid onset
of action. In oncological population, depression is quite frequent and difficult to treat because of the particular sensitivity
of cancer patients to the antidepressants’ side effects.
Goals of work The aims of this study were to evaluate efficacy, safety and tolerability of low doses of amisulpride (50 mg) in oncological,
depressed patients during chemotheraphy.
Materials and methods One hundred six consecutive cancer outpatients with depressive symptoms were treated in a prospective, intention to treat,
4-week study, and were evaluated in single-blind with Montgomery Asberg rating scale for depression (MADRS), clinical global
impression (CGI) and dosage record treatment emergent symptom scale (DOTES) to assess side effects of treatment.
Main results After 4 weeks of treatment, scores of MADRS and CGI significantly improved (p < 0.002; p < 0.001, respectively), with a reduction of depressive symptoms concerning both emotional (such as apparent sadness, reported
sadness, inner tension, etc.) and physical cluster (such as lack of appetite, reduction in weight, tiredness and insomnia)
with good tolerability (only two patients dropped out).
Conclusions This study is the first trial on the use of amisulpride in a cohort of oncological, depressed patients during chemotherapy.
Amisulpride demonstrated high efficacy and safety. Controlled studies are needed to confirm these preliminary data. 相似文献